Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

The fibronectin III-1 domain activates a PI3-Kinase/Akt signaling pathway leading to αvβ5 integrin activation and TRAIL resistance in human lung cancer cells

Authors: Christina Cho, Carol Horzempa, David Jones, Paula J. McKeown-Longo

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

Fibronectin is a mechanically sensitive protein which is organized in the extracellular matrix as a network of interacting fibrils. The lung tumor stroma is enriched for fibronectin which is thought to contribute to metastasis and drug resistance. Fibronectin is an elastic, multi-modular protein made up of individually folded domains, some of which can stretch in response to increased mechanical tension. Very little is known about the relationship of fibronectin’s unfolded domains to lung cancer resistance to chemotherapy. In the present study, we evaluated the impact of unfolding the first Type III domain of fibronectin (FnIII-1c) on TNF-related apoptosis inducing ligand (TRAIL) resistance.

Methods

NCI-H460 non-small cell lung cancer cells were treated with FnIII-1c then assessed for TRAIL-induced apoptosis. Subsequent analysis of FnIII-1c-mediated signaling pathways was also completed. Human non-small cell lung cancer tissue sections were assessed for the expression of vitronectin by immunohistochemistry.

Results

FnIII-1c inhibited TRAIL-induced activation of caspase 8 and subsequent apoptosis in NCI-H460 lung cancer cells. FnIII-1c treatment was associated with the activation of the phosphatidylinositol-3-kinase/alpha serine/threonine kinase (PI3K/Akt) pathway and the αvβ5 integrin receptor for vitronectin, both of which were required for TRAIL resistance. Immunohistochemical staining of sections from non-small cell lung cancers showed that vitronectin was localized around blood vessels and in the tumor-stroma interface.

Conclusions

Unfolding of Type III domains within the fibronectin matrix may promote TRAIL resistance through the activation of a PI3K/Akt/αvβ5 signaling axis and point to a novel mechanism by which changes in secondary structure of fibronectin contribute to cancer cell resistance to apoptosis.
Literature
1.
2.
von Pawel J, Harveyt JH, Spigel DR, Dediu M, Reck M, Cebotaru CL, Humphreys RC, Gribbin JJ, Fox NL, Camidge DR. Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor I (TRAIL-R1), in combination with iipaclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Clin Lung Cancer. 2014;15:188–96.CrossRef
3.
Mellier G, Huang S, Shenoy K, Pervaiz S. TRAILing death in cancer. Mol Aspects Med. 2010;31:93–112.CrossRefPubMed
4.
Jin H, Yang R, Ross J, Fong S, Carano R, Totpal K, Lawrence D, Zheng Z, Koeppen H, Stern H, et al. Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Clin Cancer Res. 2008;14:7733–40.CrossRefPubMed
5.
Spierings DCJ, de Vries EGE, Timens W, Groen HJM, Boezen HM, de Jong S. Expression of TRAIL and TRAIL death receptors in Stage III non-small cell lung cancer tumors. Clin Cancer Res. 2003;9:3397–405.PubMed
6.
Gee EP, Ingber DE, Stultz CM. Fibronectin unfolding revisited: modeling cell traction-mediated unfolding of the tenth type-III repeat. PLoS ONE. 2008;3, e2373.CrossRefPubMedPubMedCentral
7.
Zerlaught G, Wolf G. Plasma fibronectin as a marker for cancer and other diseases. Am J Med. 1984;77:685–9.CrossRef
8.
Nagai H, Isemura M, Arai H, Abe T, Shimoda S, Motomiya M, Sato H, Hashimoto K, Takusagawa K, Konno K. Pattern of fibronectin distribution in human lung cancer. J Cancer Res Clin Oncol. 1986;112:1–5.CrossRefPubMed
9.
Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438:820–7.CrossRefPubMedPubMedCentral
10.
11.
Oberhauser AF, Badilla-Fernandez C, Carrion-Vazquez M, Fernandez JM. The mechanical hierarchies of fibronectin observed with single-molecule AFM. J Mol Biol. 2002;319:433–47.CrossRefPubMed
12.
Gao M, Craig D, Lequin O, Campbell ID, Vogel V, Schulten K. Structure and functional significance of mechanically unfolded fibronectin type III1 intermediates. Proc Natl Acad Sci. 2003;100:14784–9.CrossRefPubMedPubMedCentral
13.
Antia M, Baneyx G, Kubow KE, Vogel V. Fibronectin in aging extracellular matrix fibrils is progressively unfolded by cells and elicits an enhanced rigidity response. Farady Discuss. 2008;139:229–49.CrossRef
14.
Baneyx G, Baugh L, Vogel V. Fibronectin extension and unfolding within cell matrix fibrils controlled by cytoskeletal tension. Proc Natl Acad Sci USA. 2002;99:14464–8.CrossRef
15.
Smith ML, Gourdon D, Little WC, Kubow KE, Eguiluz RA, Luna-Morris S, Vogel V. Force-induced unfolding of fibronectin in the extracellular matrix of living cells. PLoS Biol. 2007;5(e268):2243–54.
16.
Wang K, Andresen Eguiluz RC, Wu F, Seo BR, Fischbach C, Gourdon D. Stiffening and unfolding of early deposited-fibronectin increase proangiogenic factor secretion by breast cancer-associated stromal cells. Biomaterials. 2015;54:63–71.CrossRefPubMedPubMedCentral
17.
Hocking DC, Sottile J, McKeown-Longo PJ. Fibronectin's III-1 module contains a conformation-dependent binding site for the amino-terminal region of fibronectin. J Biol Chem. 1994;269:19183–7.PubMed
18.
Bazzoni G, Shih D-T, Buck CA, Hemler ME. Monoclonal antibody 9EG7 defines a novel β1 integrin epitope induced by soluble ligand and manganese, but inhibited by calcium. J Biol Chem. 1995;270:25570–7.CrossRefPubMed
19.
Memmo LM, McKeown-Longo P. The αvβ5 integrin functions as an endocytic receptor for vitronectin. J Cell Sci. 1998;111:425–33.PubMed
20.
Busby TF, Argraves WS, Brew SA, Pechik I, Gilliland GL, Ingham KC. Heparin binding by fibronectin module III-13 involves six discontinuous basic residues brought together to form a cationic cradle. J Biol Chem. 1995;270:18558–62.CrossRefPubMed
21.
Schwartz MA. Signaling by integrins: implications for tumorigenesis. Cancer Res. 1993;53:1503–6.PubMed
22.
23.
Gendron S, Couture J, Aoudjit F. Integrin α2β1 inhibits Fas-mediated apoptosis in T lymphocytes by protein phosphatase 2A-dependent activation of the MAPK/ERK pathway. J Biol Chem. 2003;278:48633–43.CrossRefPubMed
24.
Albert JM, Cao C, Geng L, Leavitt L, Hallahan DE, Lu B. Integrin αvβ3 antagonist Cilengitide enhnaces efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. Int J Radiat Oncol Biol Phys. 2006;65:1536–43.CrossRefPubMed
25.
Zheng Y, Ritzenthaler JD, Roman J, Han S. Nicotine stimulates human lung cancer cell growth by inducing fibronectin expression. Am J Respir Cell Mol Biol. 2007;376:681–90.CrossRef
26.
Somanath PR, Kandel ES, Hay N, Byzova TV. Akt1 signaling regulates integrin activation, matrix recogniton, and fibronectin assembly. J Biol Chem. 2007;282:22964–76.CrossRefPubMedPubMedCentral
27.
28.
Smith JW, Vestal DJ, Irwin SV, Burke TA, Cheresh DA. Purification and functional characterization of integrin αvβ5: an adhesion receptor for vitronectin. J Biol Chem. 1990;265:11008–13.PubMed
29.
Han JY, Kim HS, Lee SH, Park WS, Lee JY, Yoo NJ. Immunohistochemical expression of integrins and extracellular matrix proteins in non-small cell lung cancer: correlation with lymph node metastasis. Lung Cancer. 2003;41:66–70.CrossRef
30.
Fornaro M, Plescia J, Chheang S, Tallini G, Zhu YM, King M, Altieri DC, Languino LR. Fibronectin protects prostate cancer cells from tumor necrosis factor-α-induced apoptosis via the AKT/survivin pathway. J Biol Chem. 2003;278:50402–11.CrossRefPubMed
31.
Hetland G, Pettersen HB, Mollnes TE, Johnson E. S-protein is synthesized by human monocytes and macrophages in vitro. Scand J Immunol. 1989;29:15–21.CrossRefPubMed
32.
33.
34.
Morla A, Ruoslahti E. A fibronectin self-assembly site involved in fibronectin matrix assembly: reconstruction in a synthetic peptide. J Cell Biol. 1992;118:421–9.CrossRefPubMed
35.
Zhong C, Chrzanowska-Wodnicka M, Brown J, Shaub A, Belkin AM, Burridge K. Rho-mediated contractility exposes a cryptic site in fibronectin and induces fibronectin matrix assembly. J Cell Biol. 1998;141:539–51.CrossRefPubMedPubMedCentral
36.
Hocking DC, Titus PA, Sumagin R, Sarelius IH. Extracellular matrix fibronectin mechanically couples skeletal muscle contraction with local vasodilation. Circ Res. 2008;102:372–9.CrossRefPubMed
37.
Yao R, Sui A, Wang Z, Liu S, Zhou Q, Liu X, Zhang H. Induction of non-small cell lung carcinoma apoptosis using soluble RGD-TRAIL by targeting the integrin receptor of tumor cells. Mol Med Rep. 2012;6:1355–60.PubMed
38.
Bordeleau F, Alcoser TA, Reinhart-King CA. Physical biology in cancer. 5. The rocky road of metastasis: the role of cytoskeletal mechanics in cell migratory response to 3D matrix topography. Am J Physiol Cell Physiol. 2014;306:C110–20.CrossRefPubMed
39.
Kelsh RM, McKeown-Longo PJ. Topographical changes in extracellular matrix: activation of TLR4 signaling and solid tumor progression. Trends in Cancer Res. 2013;9:1–13.
40.
41.
Kubow KE, Klotzsch E, Smith ML, Gourdon D, Little WC, Vogel V. Crosslinking of cell-derived 3D scaffolds up-regulates the stretching and unfolding of new extracellular matrix assembled by reseeded cells. Integr Biol. 2009;1:635–48.CrossRef
42.
43.
Wan AM, Chandler EM, Madhavan M, Infanger DW, Ober CK, Gourdon D, Malliaras GG, Fischbach C. Fibronectin conformation regulates the proangiogenic capability of tumor-associated adipogenic stromal cells. Biochim Biphys Acta. 1830;2013:4314–20.
44.
Wang X, Chen W, Zeng W, Bai L, Tesfaigzi Y, Belinsky SA, Lin Y. Akt-mediated eminent expression of c-FGLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxcity to lung cancer cells. Mol Cancer Ther. 2008;7:1156–63.CrossRefPubMedPubMedCentral
45.
Li Z, Xu X, Bai L, Chen W, Lin Y. Epidermal growth factor receptor-mediated tissue transglutaminase overexpression couples acquired tumor necrosis factor-related apoptosis-inducing ligand resistance and migration through c-FLIP and MMP-9 proteins in lung cancer cells. J Biol Chem. 2011;286:21164–72.CrossRefPubMedPubMedCentral
46.
Enyu L, Zhengchuan N, Jiayong W, Benjia L, Qi S, Ruixi Q, Cheng P, Khan AQ, Wei S, Jun N. Integrin β6 can be translationally regulated by eukaryotic initiation factor 4E: contributing to colonic tumor malignancy. Tumour Biol. 2015;36:6541–50.CrossRefPubMed
47.
Byzova TV, Goldman CK, Pampori N, Thomas KA, Bett A, Shattil SJ, Plow EF. A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Mol Cell. 2000;6:851–60.PubMed
48.
Guidetti GF, Canobbio I, Torti M. PI3K/Akt in platelet integrin signaling and implications in thrombosis. Adv Biol Regul. 2015;59:36–52.CrossRefPubMed
49.
50.
Fedorenko IV, Abel EV, Koomen JM, Fang B, Wood ER, Chen YA, Fisher KJ, Iyengar S, Dahlman KB, Wargo JA et al. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene. 2015;15. doi:10.​1038/​-onc.​2015.​188.
51.
He Y, Wang Y, Liu H, Xu X, He S, Tang J, HGuang Y, Milao X, Wu Y, Wang Q, et al. Pyruvate kinase isoform (PKM2) participates in multiple myeloma cell proliferation, adhesion and chemoresistance. Leuk Res. 2015;39:1428–36.CrossRefPubMed
52.
Layani-Bazar A, Skornick I, Berrebi A, Pauker MH, Noy E, Silberman A, Albeck M, Longo DL, Kalechman Y, Sredni B. Redox modulation of adjacent thiols in VLA-4 by AS101 convertys myeloid leukemia cells from a drug-resistant to drug-sensitive state. Cancer Res. 2014;74:3092–103.CrossRefPubMed
53.
Jiang X, Wang J, Zhang K, Tang S, Ren C, Chen Y. The role of CD29-ILK-Akt signaling-mediated epithelial-mesenchymal transition of liver epithelial cells and chemoresistance and radioresistance in hepatocellular carcinoma cells. Med Oncol. 2015;32:141. doi:10.​1007/​s12032-015-0595-x.CrossRefPubMed
54.
55.
56.
57.
Graf R, Barbero S, Keller N, Chen L, Uryu S, Schlaepfer D, Stupack D. Src-inducible association of CrkL with procaspase-8 promotes cell migration. Cell Adh Migr. 2013;7:362–9.CrossRefPubMedPubMedCentral
58.
Böger C, Kalthoff H, Goodman SL, Behrens H-M, Röcken C. Integrins and their ligands are expressed in non-small cell lung cancer but not correlated with parameters of disease progression. Vichows Arch. 2014;464:69–78.CrossRef
59.
Zheng M, Jones DM, Horzempa C, Prasad A, McKeown-Longo PM. The first type III domain of fibronectin is associated with the expression of cytokines within the lung tumor microenvironment. J Cancer. 2011;2:478–83.CrossRefPubMedPubMedCentral
Metadata
Title
The fibronectin III-1 domain activates a PI3-Kinase/Akt signaling pathway leading to αvβ5 integrin activation and TRAIL resistance in human lung cancer cells
Authors
Christina Cho
Carol Horzempa
David Jones
Paula J. McKeown-Longo
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2621-6

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Research article

Evaluation of TgH(CX3CR1-EGFP) mice implanted with mCherry-GL261 cells as an in vivo model for morphometrical analysis of glioma-microglia interaction

Research article

MIR494 reduces renal cancer cell survival coinciding with increased lipid droplets and mitochondrial changes

Research article

Incidence and risk of hypertension in patients newly treated for multiple myeloma: a retrospective cohort study

Research article

Environmental, maternal, and reproductive risk factors for childhood acute lymphoblastic leukemia in Egypt: a case-control study

Research article

Neutrophil-to-lymphocyte ratio is a prognostic marker in bladder cancer patients after radical cystectomy

Research article

TNF-alpha promotes lymphangiogenesis and lymphatic metastasis of gallbladder cancer through the ERK1/2/AP-1/VEGF-D pathway
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits